Hemostemix Competitors

Emerald Health Therapeutics (CVE:EMH) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Profitability

This table compares Emerald Health Therapeutics and Hemostemix's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Emerald Health Therapeutics and Hemostemix's revenue, earnings per share and valuation.

Hemostemix has lower revenue, but higher earnings than Emerald Health Therapeutics. Hemostemix is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Emerald Health Therapeutics and Hemostemix, as provided by MarketBeat.com.

Summary

Emerald Health Therapeutics beats Hemostemix on 2 of the 3 factors compared between the two stocks.

IntelGenx Technologies (CVE:IGX) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares IntelGenx Technologies and Hemostemix's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares IntelGenx Technologies and Hemostemix's revenue, earnings per share and valuation.

Hemostemix has lower revenue, but higher earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Hemostemix, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for IntelGenx Technologies and Hemostemix, as provided by MarketBeat.com.

Summary

IntelGenx Technologies beats Hemostemix on 2 of the 3 factors compared between the two stocks.

Quest PharmaTech (CVE:QPT) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Quest PharmaTech and Hemostemix's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Quest PharmaTech and Hemostemix's revenue, earnings per share and valuation.

Quest PharmaTech has higher revenue and earnings than Hemostemix. Hemostemix is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Quest PharmaTech and Hemostemix, as provided by MarketBeat.com.

Summary

Quest PharmaTech beats Hemostemix on 3 of the 3 factors compared between the two stocks.

Ceapro (CVE:CZO) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Ceapro and Hemostemix's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Ceapro and Hemostemix's revenue, earnings per share and valuation.

Ceapro has higher revenue and earnings than Hemostemix. Hemostemix is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ceapro and Hemostemix, as provided by MarketBeat.com.

Summary

Ceapro beats Hemostemix on 3 of the 3 factors compared between the two stocks.

Crescita Therapeutics (TSE:CTX) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Crescita Therapeutics and Hemostemix's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Crescita Therapeutics and Hemostemix's revenue, earnings per share and valuation.

Crescita Therapeutics has higher revenue and earnings than Hemostemix. Hemostemix is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Crescita Therapeutics and Hemostemix, as provided by MarketBeat.com.

Summary

Crescita Therapeutics beats Hemostemix on 3 of the 3 factors compared between the two stocks.

Kane Biotech (CVE:KNE) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Profitability

This table compares Kane Biotech and Hemostemix's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Kane Biotech and Hemostemix's revenue, earnings per share (EPS) and valuation.

Hemostemix has lower revenue, but higher earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Hemostemix, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Kane Biotech and Hemostemix, as provided by MarketBeat.

Summary

Kane Biotech beats Hemostemix on 2 of the 3 factors compared between the two stocks.